- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04349995
Amplatzer PFO Occluder Post-marketing Surveillance Study (PFO PMS Jpn)
June 6, 2023 updated by: Abbott Medical Devices
The purpose of the Amplatzer PFO Occluder post-marketing clinical use surveillance study is to observe the frequency, type and degree of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect safety and efficacy information for evaluating the results of the clinical use.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Based on the Ministerial Ordinance on Good Post-marketing Study Practice for Medical Device, the Surveillance will register patients with patent foramen ovale (PFO) who have experienced a PFO-related cryptogenic cerebral infarction (including diagnosed paradoxical cerebral embolism) or transient ischemic attack (determined by positive head imaging such as DWI) in whom an Amplatzer PFO Occluder implant was attempted (Marketing Approval No. 30100BZX00024000, date May 28, 2019, hereinafter referred to as "PFO occluder").
Study Type
Observational
Enrollment (Actual)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minato
-
Mita, Minato, Japan, 108-6304
- Abbott Medical Japan LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients will be considered registered upon insertion of the Amplatzer PFO Occluder delivery system into the body
Description
Inclusion Criteria:
- Refer to Amplatzer PFO occluder IFU
Exclusion Criteria:
- Refer to Amplatzer PFO occluder IFU
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Amplatzer PFO Occluder
Percutaneous PFO Closure using Amplatzer PFO occluder
|
Percutaneous PFO closure using Amplatzer PFO Occluder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
device- or procedure related SAE rate
Time Frame: up to 30 Days
|
device- or procedure related serious adverse events (SAEs) through 30 days
|
up to 30 Days
|
PE, DVT and ischemic stroke and atrial fibrillation rate
Time Frame: beyond 30 days through 3 years
|
rate of pulmonary embolism (PE), deep vein thrombosis (DVT), ischemic stroke and atrial fibrillation beyond 30 days through 3 years
|
beyond 30 days through 3 years
|
Effective PFO closure
Time Frame: At 1 year
|
Effective closure of the PFO at 1 year
|
At 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2019
Primary Completion (Estimated)
January 30, 2024
Study Completion (Estimated)
May 28, 2026
Study Registration Dates
First Submitted
April 14, 2020
First Submitted That Met QC Criteria
April 14, 2020
First Posted (Actual)
April 16, 2020
Study Record Updates
Last Update Posted (Actual)
June 8, 2023
Last Update Submitted That Met QC Criteria
June 6, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABT-CIP-10278
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PFO - Patent Foramen Ovale
-
Carag AGCompleted
-
W.L.Gore & AssociatesRecruitingStroke | PFO - Patent Foramen OvaleUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruitingMigraine | PFO - Patent Foramen OvaleChina
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
-
Hillerod Hospital, DenmarkTerminatedStroke | Patent Foramen Ovale | TIA | PFODenmark
-
W.L.Gore & AssociatesRecruitingStroke | TIA | Cryptogenic Stroke | PFO - Patent Foramen OvaleJapan
-
Abbott Medical DevicesApproved for marketingPatent Foramen Ovale | PFO
-
W.L.Gore & AssociatesRecruitingMigraine | Patent Foramen Ovale | PFO - Patent Foramen OvaleUnited States
-
Occlutech International ABActive, not recruitingStroke | PFO - Patent Foramen OvaleFrance, Germany, Italy, Canada
Clinical Trials on Amplatzer PFO Occluder
-
Abbott Medical DevicesCompleted
-
Abbott Medical DevicesTerminatedMigraine | Patent Foramen Ovale | Migraine With Aura | PFOUnited Kingdom, Germany, Canada, Switzerland
-
Abbott Medical DevicesRecruitingStroke | Patent Foramen OvaleUnited States, Germany, Canada, Switzerland, Italy, Portugal, United Kingdom
-
Abbott Medical DevicesApproved for marketingPatent Foramen Ovale | PFO
-
Abbott Medical DevicesRecruitingPFO - Patent Foramen Ovale | VSD - Muscular Ventricular Septal Defect | PIVSD - Post Infarct Muscular Ventricular Septal Defect | ASD - Atrial Septal DefectSpain, Germany, Poland, France, Italy, Netherlands, Switzerland
-
Nobles Medical Technologies II IncSuspendedForamen Ovale, Patent | Stroke, IschemicUnited States, Italy
-
Nobles Medical Technologies II IncEnrolling by invitationForamen Ovale, Patent | Septal Defect, Atrial | Septal Defect, HeartUnited States, Italy
-
China National Center for Cardiovascular DiseasesRecruiting
-
Gachon University Gil Medical CenterCompletedPatent Foramen Ovale | Closure; Foramen OvaleKorea, Republic of